EP3258967A4 - Bivalent antibody directed against nkg2d and tumor associated antigens - Google Patents

Bivalent antibody directed against nkg2d and tumor associated antigens Download PDF

Info

Publication number: EP3258967A4
Authority: EP; European Patent Office
Prior art keywords: directed against; associated antigens; tumor associated; antibody directed; bivalent antibody
Prior art date: 2015-02-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16753226.6A

Other languages

German (de)

French (fr)

Other versions

EP3258967A2 (en

Inventor

Michael Caligiuri

Wing Keung Chan

Jianhua Yu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ohio State Innovation Foundation

Original Assignee

Ohio State Innovation Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-02-20

Filing date

2016-02-22

Publication date

2018-10-03

2016-02-22 Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation

2017-12-27 Publication of EP3258967A2 publication Critical patent/EP3258967A2/en

2018-10-03 Publication of EP3258967A4 publication Critical patent/EP3258967A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP16753226.6A 2015-02-20 2016-02-22 Bivalent antibody directed against nkg2d and tumor associated antigens Withdrawn EP3258967A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562118561P	2015-02-20	2015-02-20
US201562119645P	2015-02-23	2015-02-23
PCT/US2016/018955 WO2016134371A2 (en)	2015-02-20	2016-02-22	Bivalent antibody directed against nkg2d and tumor associated antigens

Publications (2)

Publication Number	Publication Date
EP3258967A2 EP3258967A2 (en)	2017-12-27
EP3258967A4 true EP3258967A4 (en)	2018-10-03

Family

ID=56689448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16753226.6A Withdrawn EP3258967A4 (en)	2015-02-20	2016-02-22	Bivalent antibody directed against nkg2d and tumor associated antigens

Country Status (8)

Country	Link
US (1)	US10973914B2 (en)
EP (1)	EP3258967A4 (en)
JP (1)	JP2018510623A (en)
KR (1)	KR102606190B1 (en)
CN (1)	CN107530424A (en)
AU (1)	AU2016219785B2 (en)
CA (1)	CA2977350C (en)
WO (1)	WO2016134371A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2016246457B2 (en)	2015-04-06	2020-10-15	Cytoimmune Therapeutics, Inc.	EGFR-directed car therapy for glioblastoma
WO2018148445A1 (en)	2017-02-08	2018-08-16	Adimab, Llc	Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MA47465A (en) *	2017-02-10	2019-12-18	Dragonfly Therapeutics Inc	PROTEINS BINDING BCMA, NKG2D AND CD16
EP3579878A4 (en) *	2017-02-10	2020-11-18	Dragonfly Therapeutics, Inc.	Proteins binding psma, nkg2d and cd16
JP2020508998A (en)	2017-02-20	2020-03-26	ドラゴンフライセラピューティクス，インコーポレイテッド	Proteins that bind to CD123, NKG2D and CD16
KR20240060739A (en)	2017-02-20	2024-05-08	드래곤플라이 쎄라퓨틱스, 인크.	Proteins binding her2, nkg2d and cd16
KR20240156427A (en)	2017-02-27	2024-10-29	드래곤플라이 쎄라퓨틱스, 인크.	Multispecific binding proteins targeting CEA
MX2019013995A (en) *	2017-05-23	2020-07-29	Dragonfly Therapeutics Inc	A protein binding nkg2d, cd16 and a tumor-associated antigen.
KR20200037388A (en)	2017-08-16	2020-04-08	드래곤플라이 쎄라퓨틱스, 인크.	Proteins that bind NKG2D, CD16, and EGFR, HLA-E, CCR4, or PD-L1
IL311488A (en) *	2017-08-23	2024-05-01	Dragonfly Therapeutics Inc	Proteins binding nkg2d, cd16 and a tumor-associated antigen
WO2019051308A1 (en)	2017-09-07	2019-03-14	Dragonfly Therapeutics, Inc.	Proteins binding nkg2d, cd16 and a tumor-associated antigen
EP3713959A1 (en)	2017-11-21	2020-09-30	Innate Pharma	Multispecific antigen binding proteins
JP2021512630A (en)	2018-02-08	2021-05-20	ドラゴンフライセラピューティクス，インコーポレイテッド	Antibody variable domain targeting NKG2D receptor
CA3091424A1 (en)	2018-02-20	2019-08-29	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
RU2020133311A (en) *	2018-03-16	2022-04-11	Цитоиммьюн Терапьютикс, Инк.	IMMUNOTHERAPY WITH CELLS BEARING CAR AND BISPECIFIC ANTIBODY
CA3093407A1 (en)	2018-03-23	2019-09-26	Bristol-Myers Squibb Company	Antibodies against mica and/or micb and uses thereof
WO2019195409A1 (en) *	2018-04-03	2019-10-10	Dragonfly Therapeutics, Inc.	Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams
KR20210043602A (en) *	2018-08-08	2021-04-21	드래곤플라이 쎄라퓨틱스, 인크.	Multispecific binding protein binding to BCMA, NKG2D and CD16 and methods of use thereof
EA202091888A1 (en)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR
SG11202108878VA (en) *	2019-02-18	2021-09-29	Courier Therapeutics Inc	BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS l-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER
EP3976832A1 (en)	2019-05-30	2022-04-06	Bristol-Myers Squibb Company	Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174537A (en)	2019-05-30	2022-03-11	百时美施贵宝公司	Cell localization features and combination therapies
US20220363760A1 (en)	2019-05-30	2022-11-17	Bristol-Myers Squibb Company	Multi-tumor gene signature for suitability to immuno-oncology therapy
AR119393A1 (en)	2019-07-15	2021-12-15	Hoffmann La Roche	ANTIBODIES THAT BIND NKG2D
MX2022002914A (en) *	2019-09-10	2022-06-14	Cytoimmune Therapeutics Inc	BISPECIFIC ANTIBODY CAR CELL IMMUNOTHERAPY.
JP7512394B2 (en)	2020-05-06	2024-07-08	ドラゴンフライセラピューティクス，インコーポレイテッド	Proteins that bind to NKG2D, CD16 and CLEC12A
EP4192872A1 (en)	2020-08-05	2023-06-14	Dragonfly Therapeutics, Inc.	Proteins binding nkg2d, cd16 and egfr
EP4204453A1 (en)	2020-08-31	2023-07-05	Bristol-Myers Squibb Company	Cell localization signature and immunotherapy
WO2022120179A1 (en)	2020-12-03	2022-06-09	Bristol-Myers Squibb Company	Multi-tumor gene signatures and uses thereof
CA3196999A1 (en)	2020-12-28	2022-07-07	Masano HUANG	Methods of treating tumors
AU2021411486A1 (en)	2020-12-28	2023-06-29	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
WO2022148853A1 (en)	2021-01-11	2022-07-14	F. Hoffmann-La Roche Ag	Immunoconjugates
US20240376224A1 (en)	2021-04-02	2024-11-14	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
CN118871451A (en)	2022-03-18	2024-10-29	百时美施贵宝公司	Methods for separating peptides
WO2023235847A1 (en)	2022-06-02	2023-12-07	Bristol-Myers Squibb Company	Antibody compositions and methods of use thereof
CN116023432A (en) *	2022-07-26	2023-04-28	中国药科大学	Bissialoganglioside GD2 affinity peptide and application thereof
TW202417483A (en)	2022-08-10	2024-05-01	美商默沙東有限責任公司	Proteins binding nkg2d, cd16, and ceacam5
WO2024196952A1 (en)	2023-03-20	2024-09-26	Bristol-Myers Squibb Company	Tumor subtype assessment for cancer therapy
WO2025038763A1 (en)	2023-08-15	2025-02-20	Bristol-Myers Squibb Company	Ceramic hydroxyapatite chromatography flow through method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010017103A2 (en) *	2008-08-04	2010-02-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Fully human anti-human nkg2d monoclonal antibodies
WO2011014659A2 (en) *	2009-07-29	2011-02-03	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19819846B4 (en)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalent antibody constructs
ES2307531T3 (en)	1999-09-07	2008-12-01	Societe Des Produits Nestle S.A.	METHOD FOR IMPROVING THE SKIN AND COAT OF COMPANY ANIMALS.
US20040038339A1 (en)	2000-03-24	2004-02-26	Peter Kufer	Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
ES2559763T3 (en)	2002-09-10	2016-02-15	Affimed Gmbh	CD3 specific human antibody with immunosuppressive properties
JP3803790B2 (en)	2003-02-17	2006-08-02	株式会社東北テクノアーチ	Novel diabody-type bispecific antibody
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en)	2003-05-08	2005-02-03	Protein Design Laboratories, Inc.	Therapeutic use of anti-CS1 antibodies
US20110052570A1 (en)	2005-10-26	2011-03-03	Children's Medical Center Corporation	Method to prognose response to anti-egfr therapeutics
KR20090029184A (en) *	2006-04-07	2009-03-20	더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈	Antibody Compositions and Methods of Treatment of Neoplastic Diseases
MX2008015524A (en) *	2006-06-12	2009-01-13	Trubion Pharmaceuticals Inc	Single-chain multivalent binding proteins with effector function.
WO2008034076A2 (en) *	2006-09-15	2008-03-20	The Johns Hopkins University	Cyclophosphamide in combination with immune therapeutics
CA2694488A1 (en) *	2007-07-31	2009-02-05	Medimmune, Llc	Multispecific epitope binding proteins and uses thereof
JP2012507555A (en)	2008-10-31	2012-03-29	アボットバイオセラピューティクスコーポレイション	Use of anti-CS1 antibodies in the treatment of rare diseases
US20120003695A1 (en)	2009-02-25	2012-01-05	Davidson Robert C	Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
CA2755686A1 (en) *	2009-03-16	2010-09-23	Daniel A. Vallera	Methods and compositions for bi-specific targeting of cd19/cd22
US9073990B2 (en)	2010-04-05	2015-07-07	Bar-Llan University	Protease-activatable pore-forming polypeptides
EP2614077B1 (en)	2010-09-08	2016-08-17	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Chimeric antigen receptors with an optimized hinge region
JP6224457B2 (en)	2010-11-22	2017-11-01	イネイト・ファルマ・ソシエテ・アノニム	NK cell regulatory treatment and malignant blood disease treatment method
PH12013501201A1 (en)	2010-12-09	2013-07-29	Univ Pennsylvania	Use of chimeric antigen receptor-modified t cells to treat cancer
SI2694549T1 (en)	2011-04-08	2018-12-31	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
AU2012300279A1 (en)	2011-08-26	2014-04-03	Merrimack Pharmaceuticals, Inc.	Tandem Fc bispecific antibodies
CN104126009B (en)	2011-10-07	2019-05-10	国立大学法人三重大学	Chimeric Antigen Receptor
CN104168922A (en)	2011-11-16	2014-11-26	安姆根有限公司	Methods of treating epidermal growth factor deletion mutant VIII related disorders
WO2013123061A1 (en)	2012-02-13	2013-08-22	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
EP2929032A4 (en)	2012-12-07	2016-04-06	Solazyme Inc	Genetically engineered microbial strains including chlorella protothecoides lipid pathway genes
CN103224561A (en)	2013-01-16	2013-07-31	天津大学	Staphylococcal enterotoxin micromolecule antibody and its preparation method and use
CN103113470B (en)	2013-02-27	2015-04-22	四川大学	Genetically engineered lymphocyte targeting Human EGFR (Epidermal Growth Factor Receptor), preparation method and application of genetically engineered lymphocyte
CA2904369A1 (en)	2013-03-07	2014-09-12	Baylor College Of Medicine	Targeting cd138 in cancer
US20140302037A1 (en) *	2013-03-15	2014-10-09	Amgen Inc.	BISPECIFIC-Fc MOLECULES
PL2992020T3 (en)	2013-05-03	2020-06-01	Ohio State Innovation Foundation	Cs1-specific chimeric antigen receptor engineered immune effector cells
ES2845924T3 (en)	2013-10-15	2021-07-28	Scripps Research Inst	T-cell switches with peptide chimeric antigen receptors and their uses
CN114457044A (en)	2013-10-25	2022-05-10	普西奥克瑟斯医疗有限公司	Oncolytic adenoviruses armed with heterologous genes
JP2017513818A (en)	2014-03-15	2017-06-01	ノバルティスアーゲー	Treatment of cancer using chimeric antigen receptors
RU2751660C2 (en)	2014-07-21	2021-07-15	Новартис Аг	Treatment of malignant neoplasm using humanized chimeric antigen receptor against bcma
JP2018510160A (en)	2015-03-20	2018-04-12	ブルーバードバイオ，インコーポレイテッド	Vector preparation
EP3270937A4 (en)	2015-03-26	2018-09-12	The Trustees Of Dartmouth College	Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
DK3331912T3 (en)	2015-08-04	2024-07-29	Xyphos Biosciences Inc	INSERTABLE VARIABLE FRAGMENTS OF ANTIBODIES AND MODIFIED A1-A2 DOMAINS OF NKG2D LIGANDS AND NON-NATURAL NKG2D LIGANDS THAT BIND NON-NATURAL NKG2D RECEPTORS
MA44314A (en)	2015-11-05	2018-09-12	Juno Therapeutics Inc	CHEMERICAL RECEPTORS CONTAINING TRAF-INDUCING DOMAINS, AND ASSOCIATED COMPOSITIONS AND METHODS
KR20190051956A (en)	2016-08-23	2019-05-15	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	Protein dissociation cleavable chimeric polypeptides and methods for their use

2016
- 2016-02-22 EP EP16753226.6A patent/EP3258967A4/en not_active Withdrawn
- 2016-02-22 US US15/552,078 patent/US10973914B2/en active Active
- 2016-02-22 KR KR1020177025740A patent/KR102606190B1/en active Active
- 2016-02-22 JP JP2017543915A patent/JP2018510623A/en active Pending
- 2016-02-22 CA CA2977350A patent/CA2977350C/en active Active
- 2016-02-22 AU AU2016219785A patent/AU2016219785B2/en not_active Ceased
- 2016-02-22 CN CN201680017536.1A patent/CN107530424A/en active Pending
- 2016-02-22 WO PCT/US2016/018955 patent/WO2016134371A2/en active Application Filing

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010017103A2 (en) *	2008-08-04	2010-02-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic	Fully human anti-human nkg2d monoclonal antibodies
WO2011014659A2 (en) *	2009-07-29	2011-02-03	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAUER S ET AL: "Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 285, no. 5428, 30 July 1999 (1999-07-30), pages 727 - 729, XP002177592, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.285.5428.727 *
J CHU ET AL: "CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma", LEUKEMIA, vol. 28, no. 4, 26 September 2013 (2013-09-26), pages 917 - 927, XP055133640, ISSN: 0887-6924, DOI: 10.1038/leu.2013.279 *
KWONG K Y ET AL: "Generation, Affinity Maturation, and Characterization of a Human Anti-Human NKG2D Monoclonal Antibody with Dual Antagonistic and Agonistic Activity", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 384, no. 5, 31 December 2008 (2008-12-31), pages 1143 - 1156, XP025717386, ISSN: 0022-2836, [retrieved on 20080916], DOI: 10.1016/J.JMB.2008.09.008 *
MAULIK VYAS ET AL: "Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer", TRENDS IN MOLECULAR MEDICINE, vol. 20, no. 2, February 2014 (2014-02-01), GB, pages 72 - 82, XP055501127, ISSN: 1471-4914, DOI: 10.1016/j.molmed.2013.10.006 *
PATRICK C GEDEON ET AL: "An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma", EXPERT REVIEW OF CLINICAL PHARMACOLOGY 20141101 EXPERT REVIEWS LTD. GBR, vol. 6, no. 4, 10 July 2013 (2013-07-10), UK, pages 375 - 386, XP055684229, ISSN: 1751-2433, DOI: 10.1586/17512433.2013.811806 *
See also references of WO2016134371A2 *
SHAUNA M. COLLINS ET AL: "Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC", CANCER IMMUNOLOGY, IMMUNOTHERAPY, NIH AUTHOR MANUSCRIPT, 26 October 2013 (2013-10-26), Berlin/Heidelberg, pages 1 - 15, XP055619300, ISSN: 0340-7004, DOI: 10.1007/s00262-013-1493-8 *
VEILLETTE ANDRÉ ET AL: "CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 88, no. 1, 2013, pages 168 - 177, XP028716306, ISSN: 1040-8428, DOI: 10.1016/J.CRITREVONC.2013.04.003 *

Also Published As

Publication number	Publication date
CN107530424A (en)	2018-01-02
KR20170119689A (en)	2017-10-27
JP2018510623A (en)	2018-04-19
AU2016219785A1 (en)	2017-09-07
KR102606190B1 (en)	2023-11-23
US10973914B2 (en)	2021-04-13
WO2016134371A2 (en)	2016-08-25
US20180237519A1 (en)	2018-08-23
CA2977350C (en)	2022-08-23
AU2016219785B2 (en)	2021-10-28
WO2016134371A3 (en)	2016-11-03
CA2977350A1 (en)	2016-08-25
EP3258967A2 (en)	2017-12-27

Publication	Publication Date	Title
EP3258967A4 (en)	2018-10-03	Bivalent antibody directed against nkg2d and tumor associated antigens
EP3723803A4 (en)	2021-09-15	Anti-trem2 antibodies and related methods
TWI799432B (en)	2023-04-21	Anti-ctla-4 antibodies and uses thereof
EP3532100A4 (en)	2020-11-25	Anti-pd-l1 antibodies and variants
HUE048313T2 (en)	2020-07-28	Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
EP3370769A4 (en)	2019-05-22	Antibodies specifically binding tim-3 and their uses
EP3596119A4 (en)	2021-01-13	Anti-phf-tau antibodies and uses thereof
EP3397276A4 (en)	2019-12-18	Antibodies and conjugates thereof
EP3229838A4 (en)	2018-06-06	Anti-c10orf54 antibodies and uses thereof
HK1251240A1 (en)	2019-01-25	Tumor-specific anti-egfr antibody and application thereof
EP3270965A4 (en)	2018-09-05	Cd48 antibodies and conjugates thereof
EP3362482A4 (en)	2019-08-07	Anti-pcsk9 antibodies and uses thereof
EP3645563A4 (en)	2021-03-17	Anti-fam19a5 antibodies and uses thereof
EP3233916A4 (en)	2018-06-06	Humanized anti-acth antibodies and use thereof
EP3341021A4 (en)	2019-03-13	Anti-alk antibodies and methods for use thereof
EP3658185A4 (en)	2021-07-14	Anti-tim-3 antibodies and uses thereof
EP3285805A4 (en)	2018-12-05	Therapeutic antibodies and uses thereof
HK1256816A1 (en)	2019-10-04	Novel anti-human gpvi antibodies and uses thereof
EP3126398A4 (en)	2017-11-01	Bi-specific antibodies and uses thereof
EP3199627A4 (en)	2018-03-07	Tumor antigen peptides
EP3126385A4 (en)	2018-02-21	Humanized pertussis antibodies and uses thereof
EP3675898A4 (en)	2021-09-01	Anti-lag-3 antibodies and uses thereof
EP3529273A4 (en)	2020-07-01	Anti-o1 antibodies and uses thereof
EP3496748A4 (en)	2020-01-15	Anti-o2 antibodies and uses thereof
AU2017271189A1 (en)	2019-01-24	Cytosol-penetrating antibody and use thereof

Legal Events

Date	Code	Title	Description
2016-11-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-11-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-11-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-12-27	17P	Request for examination filed	Effective date: 20171002
2017-12-27	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-12-27	AX	Request for extension of the european patent	Extension state: BA ME
2018-02-21	RIN1	Information on inventor provided before grant (corrected)	Inventor name: YU, JIANHUA Inventor name: CALIGIURI, MICHAEL Inventor name: CHAN, WING KEUNG
2018-05-30	DAV	Request for validation of the european patent (deleted)
2018-05-30	DAX	Request for extension of the european patent (deleted)
2018-10-03	A4	Supplementary search report drawn up and despatched	Effective date: 20180904
2018-10-03	RIC1	Information provided on ipc code assigned before grant	Ipc: C12N 15/63 20060101ALI20180829BHEP Ipc: C12N 1/15 20060101ALI20180829BHEP Ipc: C12N 1/19 20060101ALI20180829BHEP Ipc: C07K 16/28 20060101ALI20180829BHEP Ipc: C12N 1/21 20060101ALI20180829BHEP Ipc: A61K 39/395 20060101AFI20180829BHEP Ipc: C07H 21/00 20060101ALI20180829BHEP Ipc: C07K 16/18 20060101ALI20180829BHEP
2018-10-31	RIN1	Information on inventor provided before grant (corrected)	Inventor name: CHAN, WING KEUNG Inventor name: YU, JIANHUA Inventor name: CALIGIURI, MICHAEL
2020-04-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-05-13	17Q	First examination report despatched	Effective date: 20200416
2020-08-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-07-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-02-03	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2023-02-03	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-02-12	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-02-12	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-03-15	INTG	Intention to grant announced	Effective date: 20230213
2023-11-03	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2023-12-06	18D	Application deemed to be withdrawn	Effective date: 20230624